trending Market Intelligence /marketintelligence/en/news-insights/trending/MONnsi680H9s1MTsv9v2tg2 content esgSubNav
In This List

AstraZeneca's Breztri Aerosphere improves breathing in COPD patients

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


AstraZeneca's Breztri Aerosphere improves breathing in COPD patients

SNL Image

AstraZeneca PLC said its drug Breztri Aerosphere helped control the symptoms of patients with chronic obstructive pulmonary disease, according to data from a late-stage study.

Statistically significant results from the phase 3 clinical trial, called Ethos, showed the triple combination therapy — Breztri Aerosphere, or budesonide/glycopyrronium/formoterol fumarate, and formerly known as PT010 — at standard dose reduced moderate or severe exacerbations, when compared with dual combo medicines, in patients with moderate to very severe COPD.

The dual combo drugs used in the comparison were Bevespi Aerosphere, or glycopyrronium/formoterol fumarate, and PT009, or budesonide/formoterol fumarate. At half the dose, Breztri Aerosphere was still better than the two other therapies.

The 52-week trial, whose main goal was met, evaluated the effectiveness and safety of Breztri Aerosphere in symptomatic patients with moderate to very severe COPD and a history of exacerbation/s in the previous year.

Breztri Aerosphere's safety and tolerability were consistent with the known profiles of the dual comparators.

Cambridge, U.K.-based AstraZeneca will present results of the Ethos trial at an upcoming medical meeting.

In June, Japan's Ministry of Health, Labour and Welfare approved Breztri Aerosphere to relieve COPD symptoms. China's National Medical Products Administration has granted priority-review status to Breztri Aerosphere, with an expected decision in the second half. The medicine is also under regulatory review in the U.S. and EU with anticipated decisions in 2020.